Items Tagged ‘CD30.’

October 6, 2015

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma


The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the journal Blood. Hodgkin’s lymphoma is a type of cancer of the immune system. Standard therapy for Hodgkin’s often includes […]

View full entry

Tags: adcetris, brentuximab vedotin, CD30., Hodgkin's Lymphoma, MMAE, News, Progressive Relapsed Hodgkin's Lymphoma